DBV TECHNOLOGIES |
Market Closed -
Other stock markets
|
Pre-market 01:37:29 am | |||
| 1.212 EUR | +0.33% |
|
1.21 | -0.17% |
| Sales 2024 * | 6.53M 7M | Sales 2025 * | 4.89M 5.23M | Capitalization | 117M 125M |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -115M | Net income 2025 * | -74M -79.24M | EV / Sales 2024 * | -8.25 x |
| Net cash position 2024 * | 170M 183M | Net cash position 2025 * | 224M 240M | EV / Sales 2025 * | -21.9 x |
| P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-2.83
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | +0.33% | ||
| 1 week | -4.57% | ||
| Current month | -8.94% | ||
| 1 month | -8.60% | ||
| 3 months | -30.34% | ||
| 6 months | -45.41% | ||
| Current year | -34.45% |
1 week
1.18
1.29
1 month
1.181.40
Current year
1.101.90
1 year
1.104.30
3 years
1.1011.70
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | Nov. 05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-07-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.212 | +0.33% | 32,502 |
| 24-04-23 | 1.208 | -0.17% | 32,514 |
| 24-04-22 | 1.21 | -2.42% | 53,978 |
| 24-04-19 | 1.24 | -0.96% | 51,168 |
| 24-04-18 | 1.252 | -1.42% | 34,577 |
Real-time Euronext Paris, April 24, 2024 at 11:35 am EDT
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.212
EUR
Average target price
4.783
EUR
Spread / Average Target
+294.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.45% | 125M | |
| +5.73% | 70.78B | |
| +11.41% | 9.15B | |
| -15.34% | 4.84B | |
| +34.54% | 4.22B | |
| +5.09% | 3.92B | |
| +27.76% | 2.55B | |
| -28.33% | 2.24B | |
| -24.15% | 2.26B | |
| +6.23% | 1.92B |
- Stock Market
- Equities
- DBV Stock
